Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 126, Issue 1, Pages 215-220
Publisher
Springer Nature
Online
2010-10-25
DOI
10.1007/s10549-010-1224-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
- (2011) Alejandro Vazquez-Martin et al. CELL CYCLE
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
- (2011) Irina N. Alimova et al. CELL CYCLE
- Metformin induces unique biological and molecular responses in triple negative breast cancer cells
- (2011) Bolin Liu et al. CELL CYCLE
- Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
- (2010) K. Hosono et al. Cancer Prevention Research
- Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
- (2010) M. Bodmer et al. DIABETES CARE
- The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy
- (2009) A. Vazquez-Martin et al. ANNALS OF ONCOLOGY
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
- (2009) H. A. Hirsch et al. CANCER RESEARCH
- Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
- (2009) Philippe Bedard et al. CURRENT CANCER DRUG TARGETS
- New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
- (2009) G. Libby et al. DIABETES CARE
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
- (2009) C. J. Currie et al. DIABETOLOGIA
- Diabetes and cancer
- (2009) Paolo Vigneri et al. ENDOCRINE-RELATED CANCER
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
- (2009) Sao Jiralerspong et al. JOURNAL OF CLINICAL ONCOLOGY
- Sulphonylureas and cancer: a case–control study
- (2008) Matteo Monami et al. ACTA DIABETOLOGICA
- Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
- (2008) Vuk Stambolic et al. BREAST CANCER RESEARCH AND TREATMENT
- Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model
- (2008) Kathryn N. Phoenix et al. BREAST CANCER RESEARCH AND TREATMENT
- The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase
- (2008) M. Zakikhani et al. Cancer Prevention Research
- Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
- (2008) Pamela J. Goodwin et al. Clinical Breast Cancer
- IGF and Insulin Receptor Signaling in Breast Cancer
- (2008) Antonino Belfiore et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started